Dorian Haskard is the British Heart Foundation Sir John McMichael Professor of Cardiovascular Medicine and Head of the Vascular Sciences Section within the National Heart and Lung Institute. He is also the Head of Division of Immunology and Inflammation in the Department of Medicine.
Professor Haskard was an undergraduate at Oxford University before moving to The Middlesex Hospital Medical School and subsequently into a range of clinical and research posts in London and the US. In 1987 he was awarded a Wellcome Trust Senior Clinical Fellowship at Guy's Hospital. Following this he was appointed to Senior Clinical Lectureship at the Royal Postgraduate Medical School, Hammersmith Hospital, being promoted to Reader and then to Professor in 1995.
Professor Haskard has given numerous prestigious national and international lectures and is member of a number of learned societies and funding charities. Notably he was Chairman of the Arthritis Research Campaign Fellowship Committee (2000-2005) and Chairman of the British Atherosclerosis Society (2008-2010). He is President-elect of the International Society for Behçet’s Disease, to serve as President 2016-2010.
He has directly supervised 7 post-docs; 43 completed PhD students and many MSc, MRes and BSc students performing projects within his personal research group at Imperial College. He is currently supervising 5 PhD students (2 as primary and 3 as secondary supervisor).
The goal of Professor Haskard's research has been to achieve a greater understanding of the pathophysiology of inflammatory responses affecting the vascular system, with a view eventually to achieving more specific clinical diagnostic tests and therapies. Current work focuses on two main areas in relation to the biology of atherosclerosis: (i) mechanisms of macrophage and endothelial cell gene expression, with an emphasis on post-transcriptional RNA regulation, and (ii) the role of antibodies and complement.
See Vascular Inflammation group
Khamis RY, Haskard DO, Serruys PW, 2016, Translational interventional cardiology: a new editorial priority for EuroIntervention., Eurointervention, Vol:12, Pages:11-13
et al., 2016, Methotrexate-mediated activation of an AMPK-CREB-dependent pathway: a novel mechanism for vascular protection in chronic systemic inflammation, Annals of the Rheumatic Diseases, Vol:75, ISSN:0003-4967, Pages:439-448
et al., 2016, ORAL METFORMIN PROFOUNDLY SUPPRESSES ATHEROSCLEROTIC LESION DEVELOPMENT IN VIVO INDEPENDENTLY OF GLUCOSE-LOWERING IN A MILD HYPERLIPIDEMIC MODEL, Atherosclerosis, Vol:244, ISSN:0021-9150, Pages:E1-E1
et al., 2016, Near Infrared Fluorescence (NIRF) Molecular Imaging of Oxidized LDL with an Autoantibody in Experimental Atherosclerosis, Scientific Reports, Vol:6, ISSN:2045-2322
et al., 2016, ORAL METFORMIN PROFOUNDLY SUPPRESSES ATHEROSCLEROTIC LESION DEVELOPMENT IN VIVO INDEPENDENTLY OF GLUCOSE-LOWERING IN A MILD HYPERLIPIDEMIC MODEL, Atherosclerosis, Vol:244, ISSN:0021-9150, Pages:E2-E2